Mercado Global de Biológicos – Tendências da Indústria e Previsão para 2029

Análise e dimensão do mercado                              

Os produtos biológicos ganharam muito impulso nos últimos anos, uma vez que são utilizados para tratar uma variedade de doenças e enfermidades, como a doença de Crohn , a colite ulcerosa, a artrite reumatóide e outras doenças autoimunes. Espera-se que a utilização generalizada do produto impulsione o crescimento do mercado global de produtos biológicos nos próximos anos. Os produtos biológicos estão na vanguarda da investigação, apoiando os avanços mais recentes. Espera-se que tais avanços resultem em tratamentos revolucionários que ofereçam aos doentes novas opções de tratamento. Estão a ser desenvolvidos novos desenvolvimentos e terapêuticas exclusivas para a produção de novos produtos biológicos, indicando que o mercado global de produtos biológicos deverá ter uma perspetiva futura positiva.

A Data Bridge Market Research analisa que o mercado de produtos biológicos foi avaliado em 264 mil milhões de dólares em 2021 e deverá atingir os 596,65 mil milhões de dólares até 2029, registando um CAGR de 9,25% durante o período de previsão de 2022 a 2029 . Além dos insights de mercado, tais como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui uma análise especializada aprofundada, epidemiologia do doente, análise de pipeline, análise de preços e enquadramento regulamentar .

Âmbito do relatório e segmentação de mercado

Market Definition

Biologics, commonly referred to as biological medications, are disease-modifying antirheumatic drugs (DMARDs) that are manufactured from live creatures or contain living organism components. Vaccines, blood, blood components, tissues, cells, allergies, genes, and recombinant proteins are among the items derived from humans, insects, microbes, animals, plants, and birds. These products regulate the development of essential proteins, alter human hormones and cells, and produce compounds that either activate or suppress the immune system. They also alter the way natural biologic intracellular and cellular activities function.

Biologics Market Dynamics

Drivers

• Rise in the prevalence of chronic diseases

The surging prevalence of chronic diseases is a major factor driving the biologics market's growth rate during the forecast period of 2022-2029. As per World Health Organization (WHO), chronic diseases kill more than 41 million people worldwide each year. The most common chronic disease, cardiovascular disease, kills 17.9 million people per year, followed by cancer, diabetes and respiratory disorders. These four groups are responsible for 80% of all chronic disease mortality. Chronic diseases have prompted the development of sophisticated diagnostics and therapeutics. Biologics are medicines that have been genetically modified to target a portion of the immune system that causes inflammation.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of biologics market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the biologics market. Additionally, sedentary lifestyle of people and surging geriatric population will result in the expansion of biologics market. Along with this, favourable reimbursement policies will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the biologics market growth. In addition, scientists and researchers are studying species and expression systems to improve biological products' productivity. In addition, a number of pharmaceutical companies are conducting research and development (R and D) to increase the efficacy of oral medications for rheumatoid arthritis and Crohn's disease. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the biologics market during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the biologics market. Additionally, lack of awareness about the utilization of biologics in research centers will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029. Biologics are sensitive to heat and light, due to which they require a superior refrigeration procedure that is not consistent over the world. This is estimated to obstruct the market's growth rate. .

This biologics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biologics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Biologics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Biologics Market

The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had a huge impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact. The coronavirus pandemic had a significant influence on medicine development, production, supply, and the businesses of different healthcare corporations around the world. The outbreak has resulted in the shutdown of industrial establishments, with the exception of those that manufacture critical commodities, and disruptions in product supply chains. As a result, the COVID-19 outbreak had impacted the economy in three ways: directly influencing production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets.

On the brighter side, during the pandemic, there was a high need for biologics due to the increased COVID-19 burden, which further fuelled the market's growth rate. The National Research Council of Canada and CanSino Biologics, located in China, partnered in May 2020 to develop a COVID-19 vaccine for clinical use in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccination that is currently being developed in Wuhan, China. As a result, the COVID-19 outbreak had a positive impacted on the biologics market. Furthermore, the number of research and development activities on biologics for the treatment of COVID-19 is also increased. Additionally, the governments of various countries are also taking new initiatives for promoting the healthcare sector and ensuring the availability of biologics

Recent Development

• In November 2021, Bristol-Myers Squibb Company had received the U.S. Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA's Real-Time Oncology Examine (RTOR) pilot programme was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.

Global Biologics Market Scope

The biologics market is segmented on the basis of type, drug class, therapeutic application, source, manufacturing, drug type, mode of purchase, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Tumor Necrosis Factor (TNF) Inhibitor
• T-cell Inhibitor
• Selective Co-stimulation Modulators
• Interleukin-6 (IL-6) or Interleukin-17 Blocker
• Interleukin-1 (IL-1) Blocker
• B-cell Inhibitor

Drug Class

• Monoclonal Antibody
• Recombinant Insulin
• Vaccine
• Blood Factor
• Human Growth Hormone
• Erythropoietin
• Fusion Protein
• Recombinant Enzyme
• Interferon
• Colony-stimulating Factor
• Gene Therapy
• Cell Therapy
• Oligonucleotides
• Others
• Peptide
• Botulinum Toxin
• Others

Therapeutic Application

• Oncology
• Autoimmune/Immunologic Diseases
• Metabolic Disorders
• Ophthalmic Diseases
• Respiratory Disorders
• Inflammatory Bowel Diseases (IBDs)
• Neurological Disorders
• Cardiovascular Diseases (CVDs)
• Musculoskeletal Disorders (MSDs)
• Infectious Diseases
• Others

Source

• Microbial
• Mammalian
• Others

Manufacturing

• Outsourced
• In-House

Drug Type

• Branded Drugs
• Generic Drugs

Mode of Purchase

• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Dosage Form

• Injection
• Tablets
• Others

Route of Administration

• Parenteral
• Oral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Biologics Market Regional Analysis/Insights

O mercado dos produtos biológicos é analisado e são fornecidos insights e tendências do tamanho do mercado por país, tipo de medicamento, classe de medicamentos, aplicação terapêutica, fonte, fabrico, tipo de medicamento, modo de compra, forma farmacêutica, via de administração , utilizadores finais e canal de distribuição como acima referenciado.

Os países abrangidos no relatório de mercado de produtos biológicos são os EUA, Canadá e México na América do Norte, Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa, China, Japão, Índia, Coreia do Sul, Singapura, Malásia, Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC) na Ásia-Pacífico (APAC), Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Israel , Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA), Brasil, Argentina e Resto da América do Sul como parte da América do Sul

A América do Norte domina o mercado biológico em termos de quota de mercado e receitas de mercado e continuará a florescer o seu domínio durante o período de previsão. Isto deve-se à presença dos principais players e o aumento dos gastos com a saúde irá impulsionar ainda mais a taxa de crescimento do mercado nesta região. Além disso, o aumento das colaborações estratégicas para o desenvolvimento de tratamento biológico para doenças agudas e crónicas impulsionará ainda mais a taxa de crescimento do mercado nesta região.

Prevê-se que a Ásia-Pacífico cresça durante o período de previsão de 2022-2029 devido ao aumento da prevalência da artrite reumatóide e das doenças renais e hepáticas nesta região. Além disso, o desenvolvimento das infraestruturas de saúde e o aumento da população geriátrica impulsionarão ainda mais a taxa de crescimento do mercado nesta região.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Análise do cenário competitivo e da quota de mercado dos produtos biológicos

O panorama competitivo do mercado de produtos biológicos fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado dos produtos biológicos.

Alguns dos principais players que operam no mercado dos produtos biológicos são:

• (EUA)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suíça)
• Mylan NV (EUA)
• (Israel)
• Sanofi (França)
• Boehringer Ingelheim International GmbH. (Alemanha)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (EUA)
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd. (Suíça)
• Empresa Bristol-Myers Squibb (EUA)
• Eli Lilly and Company (EUA)
• Allergan (Irlanda)
• Abbott (EUA)
• LEO Pharma A/S (Dinamarca)
• Sun Pharmaceutical Industries Ltd. (Índia)
• Aurobindo Pharma (Índia)
• Tremoço (Índia)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Zydus Cadila (Índia)

SKU-56794